Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AssigneeUniversiteit Maastricht
InventorYigal M. Pinto
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.
Claims8
A method for identifying a subject at risk of developing heart failure, the method comprising measuring the level of galectin-3 in a biological sample from a human subject and comparing the level of galectin-3 to a standard level indicative of heart failure risk, wherein an elevated level of galectin-3 in the sample indicates a risk of developing heart failure.
A method of identifying a risk of developing congestive heart failure in a patient with cardiovascular disease, the method comprising measuring a level of galectin-3 in a sample from the patient and comparing it to a standard level indicative of a risk of developing congestive heart failure, wherein an elevated level of galectin-3 in the sample indicates a risk of developing congestive heart failure.
Dependencies are inferred from the claim text.